Politics & Legislation

Aptiv Solutions Executive Discusses the State of Mobile Health Technology Regulatory

June 23, 2013 OneMedPlace Team 0

OneMedRadio spoke with Cynthia Nolte, Director, Medical Device Regulatory Services for Aptiv Solutions, about the state of mobile health/health information technology regulatory, clinical trial design for mobile health technology, and what we can expect from future guidelines. The conclusions about regulating a rapidly evolving space — and the case studies that have pioneered this process — are intriguing, and indeed promising.

No Image

OneMedForumNY 2013, June 26-27

May 17, 2013 OneMedPlace Team 0

NEW YORK, October 3, 2012 – OneMedPlace has announced programming themes for its 6th Annual OneMedForum, taking place January 7-9th, 2013, at the Sir Francis Drake Hotel in San Francisco.

MAPPING THE B.R.A.I.N.

May 17, 2013 OneMedPlace Team 0

On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.

Caprion’s Proteomic Biomarkers — Diverse Clientele Leads to In-House Pipeline

April 16, 2013 OneMedPlace Team 0

Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.

Healthcare Providers an Interesting Investment Field, Not Only For Private Equity

April 15, 2013 OneMedPlace Team 0

The landscape of healthcare is changing and whoever is smart will watch closely. With the introduction of Obamacare in 2013, the US stands to see a substantial increase in the number of insured individuals. And because the correlation between time and age has always been positive, Uncle Sam will be attending to millions of North Americans turning 65 yearly, their growing healthcare bill in tow.

OneMedRadio: Vijay Aggarwal Part II

April 3, 2013 OneMedPlace Team 0

In Part II of our interview with Vijay Aggarwal, Managing Partner of the Channel Group, we explore trends in the space, reimbursement issues, and the state of equity financing. Dr. Aggarwal also discusses changing investment strategy with regards to evaluating risk factors, a more sophisticated level of proof, and an evolving emphasis on the achieving and maintaining revenue during early financing rounds.

The Briefing Room: Novartis in India, Generic Drugs, Bird Flu, Sleep Apnea

April 1, 2013 OneMedPlace Team 0

In case you missed it, Monday featured a number of interesting developments in the world of healthcare and life sciences. Most notably, a seemingly rare patent defeat may harm Novartis’ bottom line in India, but helps secure a mass population to a popular leukemia drug. India has emerged as a leading market for drug innovation, yet faces a crossroads — as legislation now protects what has become the largest generic drug market in the world. Additionally, we’re interested in some new developments in Chinese bird flu, sleep apnea, and sexual health in adolescents.

So What Happens if Medicare Stops Paying Its Bills?

April 1, 2013 Chelli Miller 0

The “elephant in the room” is the shifting, uncertain complexity of our regulatory and legislative environment. Exactly to that point, on Wednesday, March 27th Dr. Scott Gottlieb, a Forbes contributor focusing on policy, regulation, and public health posted an article entitled “Medicare Has Stopped Paying Bills For Medical Diagnostic Tests. Patients Will Feel”, which instantly caused a collective shiver among some diagnostics-focused investors and advisory groups. Experts shared their views on the Forbes article and its implications with us.